# Sonlicromanol in Post-COVID

> **NCT07298005** · PHASE2 · RECRUITING · sponsor: **Michele van Vugt** · enrollment: 80 (estimated)

## Conditions studied

- Post COVID Condition

## Interventions

- **DRUG:** Sonlicromanol
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07298005
- **Lead sponsor:** Michele van Vugt
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04
- **Primary completion:** 2027-02
- **Final completion:** 2027-03
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-04-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07298005

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07298005, "Sonlicromanol in Post-COVID". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07298005. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*